Both Marion Gruber and Phillip Krause, FDA officials, co-authored a document disputing the need for COVID-19 boosters for most people.
Marion Gruber and Phillip Krause, two FDA officials who announced they would be leaving the agency after clashing with Biden over the need for booster vaccines, were among 18 authors of a paper published in The Lancet (1) on Sept. 13, 2021 disputing the need for booster vaccines for most people.
The current administration has firmly backed booster vaccines, with the Department of Human Health and Services recently stating that they believed booster vaccines would be needed. However, others, such as World Health Organization Director-General Tedros Adhanom Ghebreyesus, have pushed back against those calling for immediate booster shots, stating that it is more pressing to increase vaccine coverage in underserved countries.
The contention of Gruber, Krause, and the other authors of the paper, “Considerations in Boosting COVID-19 Vaccine Immune Responses”, centers on the assertion that there is no substantiated scientific backing for boosters for most people. According to the paper, initial findings from randomized trials have shown strong efficacy of the vaccines.
The authors of the paper showed concern that booster vaccines might result in unintended, adverse effects in recipients, which could also cause increased vaccine mistrust in the general population. Similarly, they worry that public opinion on the efficacy of the vaccine will be undermined by calls for a booster less than a year after release.
“Although the idea of further reducing the number of COVID-19 cases by enhancing immunity in vaccinated people is appealing, any decision to do so should be evidence-based and consider the benefits and risks for individuals and society,” stated Krause et al. in the paper.
“If boosters (whether expressing original or variant antigens) are ultimately to be used,” continued Krause et al. “There will be a need to identify specific circumstances in which the direct and indirect benefits of doing so are, on balance, clearly beneficial. Additional research could help to define such circumstances.”
References:
P. Krause et al., The Lancet. io. online, DOI:10.1016/S0140-6736(21)02046-8(Sept. 13, 2021).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.